Yevhen S. Hotko

Uzhgorod, Ukraine

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Changes in morphological and immunohistochemical parameters of tumors during neoadjuvant hormone therapy in postmenopausal patients with luminal type of breast cancer.

Changes in morphological and immunohistochemical parameters of tumors during neoadjuvant hormone therapy in postmenopausal patients with luminal type of breast cancer.

Journal: Wiadomosci lekarskie (Warsaw, Poland : 1960)

Published: May 14, 2025

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial.

Journal: The Lancet. Oncology

Published: April 11, 2024

Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies.

Pharmacokinetics, safety, and efficacy of an alternative dosing regimen of sasanlimab in participants with advanced NSCLC and other malignancies.

Journal: Therapeutic advances in medical oncology

Published: February 27, 2024

PATIENT MANAGEMENT TACTICS AT DIFFERENT STAGES OF GASTROINTESTINAL STROMAL TUMORS (GIST).

PATIENT MANAGEMENT TACTICS AT DIFFERENT STAGES OF GASTROINTESTINAL STROMAL TUMORS (GIST).

Journal: Wiadomosci lekarskie (Warsaw, Poland : 1960)

Published: April 14, 2023

Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).

Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: June 30, 2016

Peculiarities of breast cancer incidence rate in urban population and implementation of screening programs in health care system.

Peculiarities of breast cancer incidence rate in urban population and implementation of screening programs in health care system.

Journal: Wiadomosci lekarskie (Warsaw, Poland : 1960)

Published: May 11, 2016

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).

Journal: Clinical colorectal cancer

Published: April 19, 2016

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 04, 2015

Receptor status of tumor as prognostic factor in patients with bilateral breast cancer.

Receptor status of tumor as prognostic factor in patients with bilateral breast cancer.

Journal: Experimental oncology

Published: January 03, 2014

Male breast cancer: clinical presentation, diagnosis, treatment.

Male breast cancer: clinical presentation, diagnosis, treatment.

Journal: Experimental oncology

Published: January 03, 2014

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 21, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026